Welcome to our dedicated page for BIONTECH news (Ticker: BNTX), a resource for investors and traders seeking the latest updates and insights on BIONTECH stock.
BioNTech SE (BNTX) is a global biotechnology pioneer advancing mRNA-based therapies for cancer and infectious diseases. This page provides investors and stakeholders with timely updates on corporate developments, clinical research milestones, and strategic initiatives shaping the future of personalized medicine.
Access official press releases, earnings reports, and regulatory filings alongside analysis of key partnerships with pharmaceutical leaders. Our curated news collection ensures you stay informed about pipeline advancements, trial results, and innovations in immunotherapy platforms.
Discover updates across critical categories including clinical trial progress, regulatory approvals, research collaborations, and manufacturing expansions. Content is rigorously verified to provide actionable insights while adhering to financial disclosure standards.
Bookmark this page for streamlined access to BioNTech's evolving role in oncology therapeutics and next-generation vaccine development. Regularly updated to reflect the company's scientific advancements and business strategy execution.
BioNTech and Pfizer have received conditional marketing authorization from the European Commission for their mRNA vaccine, COMIRNATY (BNT162b2), to prevent COVID-19 in individuals aged 16 and older. This historic achievement is based on data from a large-scale trial involving over 44,000 participants and demonstrates a vaccine efficacy rate of 95%. The EU has ordered 200 million doses, with an option for 100 million more. Immediate distribution will commence across all 27 EU member states, with ongoing monitoring of efficacy and safety for two additional years.
Pfizer and BioNTech announced a positive opinion from the EMA's CHMP recommending conditional marketing authorization for their COVID-19 vaccine (BNT162b2) for individuals 16 and older. This CMA allows for expedited approval in response to serious public health threats. The positive recommendation is based on Phase 3 clinical study data, which supports the vaccine's efficacy against COVID-19. If authorized by the European Commission, the vaccine will be available across all EU member states. The vaccine is already authorized for emergency use in over 15 countries.
The European Medicines Agency (EMA) has provided a positive opinion recommending conditional marketing authorization for the Pfizer-BioNTech COVID-19 vaccine (BNT162b2). If authorized by the European Commission, it will be the first COVID-19 vaccine available in the EU. Based on extensive Phase 3 data, the vaccine aims to combat COVID-19 for individuals aged 16 and older. This positive opinion follows numerous emergency use authorizations globally, and the vaccine has already been approved in over 15 countries.
BioNTech (BNTX) and Fosun Pharma announced a supply agreement for 100 million doses of the BNT162 mRNA COVID-19 vaccine in China, pending regulatory approval. The initial supply will come from BioNTech's facilities in Germany. This collaboration aims to enhance vaccine accessibility and affordability in China. A Phase 2 clinical trial for BNT162b2 is ongoing in Jiangsu Province, involving 960 participants to assess safety and immunogenicity. Both companies express gratitude towards the Chinese authorities for their support in combating COVID-19.
BioNTech (Nasdaq: BNTX) and Pfizer announced significant findings from their Phase 1/2 trial of the COVID-19 vaccine BNT162b2. The study involving 37 participants showed a robust immune response, including broad SARS-CoV-2-specific neutralizing antibodies, CD4+ T cell responses, and strong CD8+ T cell activation. Notably, all participants produced neutralizing antibodies, and the vaccine effectively targeted multiple spike protein regions. These results affirm a strong safety profile and sustained immune response, indicating potential for broad protection against diverse virus variants.
Pfizer and BioNTech announced a favorable FDA advisory committee vote (17 to 4) supporting Emergency Use Authorization for their COVID-19 mRNA vaccine, BNT162b2. The decision is based on comprehensive Phase 3 efficacy and safety data, showing a 95% efficacy rate in study participants. If authorized, BNT162b2 will be the first COVID-19 vaccine available in the U.S. The FDA's final decision is pending, considering the advisory committee's recommendation.
BioNTech SE (Nasdaq: BNTX) and Pfizer Inc. (NYSE: PFE) announced the publication of final efficacy results from their Phase 3 trial of the mRNA-based COVID-19 vaccine BNT162b2, involving 43,448 participants. The results indicate a 95% efficacy in preventing COVID-19 among those without prior infection, with strong performance across demographic subgroups. The trial also noted early partial protection beginning 12 days post first dose. The data are crucial for regulatory submissions to agencies like the FDA and EMA.
Health Canada has authorized the emergency use of the mRNA COVID-19 vaccine BNT162b2 developed by BioNTech and Pfizer. The companies will supply a minimum of 20 million doses to Canada in 2021, with potential upward adjustment to 76 million doses. This decision follows similar approvals in the U.K. and Bahrain. The authorization is based on extensive clinical trial data involving approximately 44,000 participants. BioNTech holds the regulatory approval, while Pfizer manages commercialization in Canada.
BioNTech SE (Nasdaq: BNTX) is set to hold a press conference on December 2, 2020, focusing on the status of its lead COVID-19 vaccine candidate, BNT162b2. The conference, conducted in English, will begin at 12:30 PM CET (6:30 AM ET), and will allow journalists to submit questions online. BioNTech, a pioneer in next-generation immunotherapy, is developing various mRNA vaccine candidates for infectious diseases while continuing its oncology pipeline. More details can be found on BioNTech's official website.
FAQ
What is the current stock price of BIONTECH (BNTX)?
What is the market cap of BIONTECH (BNTX)?
